Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Group 1 - Travere Therapeutics received full approval for its sparsentan 200/400 mg tablets, branded as Filspari, for the treatment of IgA nephropathy (IgAN) [1] - IgAN is a chronic kidney disease caused by the immune system producing abnormal antibodies [1] Group 2 - The article does not provide additional relevant content for further summarization.